For what it’s worth: the complex area of medicine value assessment

Summary

Egilman and colleagues recently investigated the therapeutic benefit of the most popular branded pharmaceuticals covered by Medicare in 2020, as determined by health technology assessment (HTA) bodies in Canada, France, and Germany. The authors concluded that many top prescribed drugs have low benefit ratings from these HTA agencies, and this information could be helpful for the future when Medicare are able to negotiate pricing as part of the Inflation Reduction Act.